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Summary
Background M5717 is the first plasmodium translation elongation factor 2 inhibitor to reach clinical development as an 
antimalarial. We aimed to characterise the safety, pharmacokinetics, and antimalarial activity of M5717 in healthy 
volunteers.
Methods This first-in-human study was a two-part, single-centre clinical trial done in Brisbane, QLD, Australia. 
Part one was a double-blind, randomised, placebo-controlled, single ascending dose study in which participants 
were enrolled into one of nine dose cohorts (50, 100, 200, 400, 600, 1000, 1250, 1800, or 2100 mg) and randomly 
assigned (3:1) to M5717 or placebo. A sentinel dosing strategy was used for each dose cohort whereby two participants 
(one assigned to M5717 and one assigned to placebo) were initially randomised and dosed. Randomisation 
schedules were generated electronically by independent, unblinded statisticians. Part two was an open-label, non-
randomised volunteer infection study using the Plasmodium falciparum induced blood-stage malaria model in 
which participants were enrolled into three dose cohorts. Healthy men and women of non-childbearing potential 
aged 18–55 years were eligible for inclusion; individuals in the volunteer infection study were required to be malaria 
naive. Safety and tolerability (primary outcome of the single ascending dose study and secondary outcome of the 
volunteer infection study) were assessed by frequency and severity of adverse events. The pharmacokinetic profile 
of M5717 was also characterised (primary outcome of the volunteer infection study and secondary outcome of the 
single ascending dose study). Parasite clearance kinetics (primary outcome of the volunteer infection study) were 
assessed by the parasite reduction ratio and the corresponding parasite clearance half-life; the incidence of 
recrudescence up to day 28 was determined (secondary outcome of the volunteer infection study). Recrudescent 
parasites were tested for genetic mutations (exploratory outcome). The trial is registered with ClinicalTrials.gov 
(NCT03261401).
Findings Between Aug 28, 2017, and June 14, 2019, 221 individuals were assessed for eligibility, of whom 66 men 
were enrolled in the single ascending dose study (eight per cohort for 50–1800 mg cohorts, randomised three 
M5717 to one placebo, and two in the 2100 mg cohort, randomised one M5717 to one placebo) and 22 men were 
enrolled in the volunteer infection study (six in the 150 mg cohort and eight each in the 400 mg and 800 mg 
cohorts). No adverse event was serious; all M5717-related adverse events were mild or moderate in severity and 
transient, with increased frequency observed at doses above 1250 mg. In the single ascending dose study, 
treatment-related adverse events occurred in three of 17 individuals in the placebo group; no individual in the 
50 mg, 100 mg, or 200 mg groups; one of six individuals in each of the 400 mg, 1000 mg, and 1250 mg groups; 
two of six individuals in the 600 mg group; and in all individuals in the 1800 mg and 2100 mg groups. In the 
volunteer infection study, M5717-related adverse events occurred in no participants in the 150 mg or 800 mg 
groups and in one of eight participants in the 400 mg group. Transient oral hypoesthesia (in three participants) 
and blurred vision (in four participants) were observed in the 1800 mg or 2100 mg groups and constituted an 
unknown risk; thus, further dosing was suspended after dosing of the two sentinel individuals in the 2100 mg 
cohort. Maximum blood concentrations occurred 1–7 h after dosing, and a long half-life was observed (146–193 h 
at doses ≥200 mg). Parasite clearance occurred in all participants and was biphasic, characterised by initial slow 
clearance lasting 35–55 h (half-life 231∙1 h [95% CI 40∙9 to not reached] for 150 mg, 60∙4 h [38∙6 to 138∙6] for 
400 mg, and 24∙7 h [20∙4 to 31∙3] for 800 mg), followed by rapid clearance (half-life 3∙5 h [3∙1 to 4∙0] for 150 mg, 
3∙9 h [3∙3 to 4∙8] for 400 mg, and 5∙5 h [4∙8 to 6∙4] for 800 mg). Recrudescence occurred in three (50%) of 
six individuals dosed with 150 mg and two (25%) of eight individuals dosed with 400 mg. Genetic mutations 
associated with resistance were detected in four cases of parasite recrudescence (two individuals dosed with 
150 mg and two dosed with 400 mg).
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Introduction
The decline in the worldwide burden of malaria achieved 
earlier in the 21st century has now plateaued,1 a situation 
exacerbated by the emergence of resistance to first-line 
artemisinin-based combination therapies in southeast 
Asia.2 An estimated 229 million cases and 409 000 deaths 
were attributable to the disease in 2019.1 The development 
of new antimalarial treatments is one important com-
ponent of the fight to reduce malaria morbidity and 
mortality. The ideal characteristics of new antimalarials 
include an ability to reduce the parasite burden rapidly; a 
long duration of activity to avoid the requirement for 
multiple dosing; activity against multiple parasite lifecycle 
stages, including dormant liver stages and transmissible 
gametocytes; an ability to be used for chemoprotection; 
and a novel mode of action to avoid cross-resistance with 
existing antimalarials.3 The combination of two or 
more compounds is probably necessary to achieve these 
properties and is considered an important strategy to 
minimise the risk of resistance emerging to a novel 
compound. Finally, as the affordability of any new 
antimalarial treatment is an important factor, the cost of 
manufacturing a candidate compound must be considered 
before investing in clinical development.3
M5717 (formerly DDD107498) is a novel antimalarial 
compound discovered through a phenotypic screen, and 
it was shown to exhibit nanomolar potency against 
Plasmodium falciparum.4,5 The molecular target of M5717 
was identified as translation elongation factor 2 (eEF2), 
which is essential for protein synthesis due to its role in 
GTP-dependent translocation of the ribosome along 
mRNA.6 Preclinical in-vitro and in-vivo analyses indicated 
that M5717 has high selectivity for plasmodium eEF2 
and activity against multiple Plasmodium spp lifecycle 
stages (including liver-stage and both asexual and sexual 
blood-stage parasites). These studies also indicated an 
acceptable safety profile and good pharmacokinetic 
properties.4 Collectively, these properties indicated the 
potential for the compound to offer single-dose cure, 
reduce transmission, and achieve chemoprotection. 
Furthermore, initial cost-of-goods estimates and likely 
human-dose projections suggested an acceptable cost 
per treatment.4 Together, the results of preclinical work 
indicated that M5717 is a promising candidate to advance 
to clinical development as a new antimalarial treatment.
This report describes the first in-human clinical trial to 
characterise the safety, tolerability, pharmacokinetics, 
and antimalarial activity of M5717 in healthy volunteers. 
Research in context
Evidence before this study
New antimalarials with novel mechanisms of action are needed 
to combat the emergence of drug resistance and to progress 
towards malaria elimination. M5717 (formerly DDD107498) 
is a new antimalarial candidate that inhibits plasmodium 
translation elongation factor 2, an enzyme essential for protein 
synthesis. We searched PubMed between Jan 1, 2010, and 
Feb 19, 2021, using the terms “plasmodium translation 
elongation factor 2 inhibitor”, “M5717”, and “DDD107498”. 
Preclinical studies showed that M5717 has potent antimalarial 
activity towards multiple Plasmodium spp lifecycle stages in 
vitro and in vivo and good pharmacokinetic properties 
amenable to use as a drug and predicted an acceptable safety 
profile in humans. Together these findings supported the 
progression of M5717 into clinical development.
Added value of this study
This is the first in-human clinical trial of M5717. This study 
integrates a single ascending dose study with a volunteer 
infection study using the Plasmodium falciparum induced 
blood-stage malaria model to characterise the safety, 
pharmacokinetics, and antimalarial activity of M5717 in 
healthy adults. Our results showed that M5717 is well tolerated 
in humans up to and including a dose of 1250 mg, with the 
incidence of M5717-related adverse events remaining low 
up to this dose, whereas mild-to-moderate and transient 
neurological adverse events were observed with dosing at 
1800 mg and 2100 mg. M5717 exhibits a pharmacokinetic 
profile characterised by a long half-life (146–193 h at doses 
≥200 mg). Single oral doses of M5717 (150 mg, 400 mg, or 
800 mg) resulted in initial clearance of asexual blood-stage 
parasitaemia with a biphasic profile, characterised by an initial 
period of slow clearance lasting 35–55 h, followed by a rapid 
clearance phase. Genetic mutations associated with resistance 
were detected in recrudescent parasites in four participants.
Implications of all the available evidence
M5717 is well tolerated in healthy adults at doses that 
clear blood-stage P falciparum, with the long half-life of 
the compound supporting the potential for single-dose 
administration with long-duration activity. Future studies to 
investigate combination therapies of M5717 with a partner 
drug exhibiting a distinct mode and rapid onset of action in 
treating clinical malaria are warranted, as are investigations 
into the use of M5717 for other indications, including 
chemoprotection and prevention of transmission.
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Our study was undertaken in two parts. The first part 
was a randomised single ascending dose study with oral 
administration of M5717 or matching placebo. The 
second part was a volunteer infection study using the 
induced blood-stage malaria model,7 in which malaria-
naive volunteers were inoculated with P falciparum-
infected erythrocytes and subsequently administered a 
single oral dose of M5717. This work represents the 
first clinical investigation of an antimalarial compound 
targeting plasmodium eEF2.
Methods
Study design and participants
This study was planned to be done in three parts. Part A 
(done as planned) was a first-in-human, double-blind, 
randomised, placebo-controlled, single ascending dose 
study. Part B was planned to be a multiple ascending 
dose study that would be done if emerging data in 
part A indicated that it would not be possible to 
administer a tolerable single dose that would achieve 
exposure over 8 days at a concentration well above 
the minimum parasiticidal concentration estimated in 
preclinical studies.4 Data from the first four cohorts of 
the single ascending dose study resulted in a decision 
not to do the multiple ascending dose study (whose 
study design and methodology are therefore not 
presented here). Part C (done as planned) was an open-
label, non-randomised volunteer infection study using 
the P falciparum induced blood-stage malaria model. 
The volunteer infection study began once the safety 
monitoring committee had reviewed data from the first 
four cohorts of the single ascending dose study and had 
determined that the exposure threshold had been 
reached.
Healthy men and women of non-childbearing potential 
aged 18–55 years were eligible for inclusion in both study 
parts (A and C); participants in the volunteer infection 
study were required to be malaria-naive (see appendix 
p 12 for full eligibility criteria). The study was done at 
Q-Pharm (Brisbane, QLD, Australia) following approval 
by the QIMR Berghofer Medical Research Institute 
Human Research Ethics Committee. All participants 
gave written informed consent before enrolment. The 
study is registered with ClinicalTrials.gov (NCT03261401).
Randomisation and masking
Participants in the single ascending dose study were 
randomised within each dose cohort (50, 100, 200, 400, 
600, 1000, 1250, 1800, or 2100 mg) to either M5717 or 
placebo in a 3:1 ratio. The randomisation schedules were 
generated electronically by independent, unmasked 
statisticians using SAS version 9.4. Participants and 
investigators were masked to the identity of the treatment 
from the time of randomisation until database lock. 
Treatment identity was concealed by the identical 
packaging, appearance, odour, and taste of M5717 and 
placebo.
Procedures
After a screening period of 26 days, participants in the 
single ascending dose study were admitted to the clinic 
2 days before dosing for baseline electrocardiograms 
(ECGs) on day –1. On dosing day (day 1), after 
randomisation, participants received a single oral dose of 
M5717 or placebo capsules (the healthcare business of 
Merck KGaA, Darmstadt, Germany) with 250 mL of water 
after fasting for at least 8 h; no food was allowed until 4 h 
after dosing. A sentinel dosing strategy was used for each 
dose cohort whereby two participants (one assigned to 
M5717 and one assigned to placebo) were initially 
randomised and dosed. The investigator reviewed blinded 
safety data up to at least 36 h after dosing before deciding 
whether to proceed with randomisation and dosing of the 
remaining six participants in the cohort. Participants 
were confined to the clinic until day 7 and returned as 
outpatients for follow-up visits until the end of the study.
The starting dose of M5717 used in the single ascending 
dose study (50 mg) was half of the maximum safe starting 
dose calculated in accordance with guidance from the 
US Food & Drug Administration.8 Dose selection for 
each subsequent cohort was decided by the safety 
monitoring committee based on safety data up to day 22 
and pharmacokinetic data up to day 7. Since data 
from the first three cohorts (50, 100, and 200 mg) 
indicated that the observed terminal half-life of M5717 
(133–145 h) was shorter than that predicted before the 
study (250 h), the safety monitoring committee approved 
a reduction of the duration of follow-up for participants 
in the remaining six cohorts from day 55 to day 44 for the 
end-of-study visit.
The volunteer infection study was done in three dose 
cohorts (150, 400, and 800 mg). After a screening period 
of 26 days, participants were inoculated intravenously 
with P falciparum-infected erythrocytes (containing 
approxi mately 2800 viable parasites) on day –8. 
Parasitaemia was monitored twice daily from the 4th 
day after the inoculation until the day of dosing with 
M5717 (day 1) on an outpatient basis by collecting blood 
samples and performing qPCR targeting the gene 
encoding P falciparum 18S rRNA.9 Participants 
were admitted to the clinic for M5717 dosing when 
parasitaemia was expected to be at least 5000 parasites 
per mL. A single oral dose of M5717 was administered 
as described for the single ascending dose study. 
Participants were confined to the clinic until day 4 and 
returned as outpatients for follow-up visits until the end 
of study visit on day 44. Participants received a standard 
curative course of artemether–lumefantrine treatment 
upon recrudescence or on day 21 if recrudescence had 
not occurred. Parasite DNA extracted from recrudescent 
P falciparum populations was subject to DNA sequence 
analysis of the P falciparum eEF2 gene that encodes the 
drug target and resistance mediator4 to investigate 
potential mutations that could confer resistance to 
M5717 (appendix p 9).
See Online for appendix
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The first cohort in the volunteer infection study was 
administered 400 mg M5717. This dose was selected 
on the basis of data obtained from a preclinical mouse 
efficacy model,4 as well as human pharmacokinetic 
data obtained from the first four cohorts of the single 
ascending dose study. A single 400 mg dose was 
estimated to maintain blood concentrations above the 
predicted minimum parasiticidal concentration for 
8 days in the majority of participants. After review of the 
data obtained in the first cohort, the safety monitoring 
committee decided to lower the dose to 150 mg for the 
second cohort to better characterise the exposure–
response relationship. After review of the data obtained 
in the 150 mg cohort, as well as pharmacokinetic and 
safety data from the 1000 mg cohort in the single 
ascending dose study, the safety monitoring committee 
decided that a third volunteer infection study cohort 
would proceed at a dose of 800 mg to further define the 
exposure–response relationship.
M5717 concentration in whole blood was determined 
using liquid chromatography tandem mass spectrometry 
(appendix p 11). A dried blood spot assay was done in the 
second and third cohorts of the volunteer infection study 
to assess the correlation of M5717 concentrations in 
whole blood with that in dried blood spots. Results of 
this analysis will be presented elsewhere. Blood 
sampling timepoints for M5717 concentration and 
parasitaemia measurements are specified in the 
appendix (p 15).
Outcomes
The primary outcomes of the single ascending dose 
study and secondary outcomes of the volunteer infection 
study were the nature, incidence, and severity of adverse 
events, as well as the incidence of clinically significant 
changes and abnormalities in safety laboratory par a-
meters (haematology, coagulation, biochemistry, and 
urinalysis), vital signs (body temperature, blood pressure, 
heart rate, and respiratory rate), and 12-lead ECGs. The 
medical assessment of adverse event severity was 
done in accordance with the Qualitative Toxicity Scale 
(mild=grade 1, moderate=grade 2, severe=grade 3, 
potentially life threatening=grade 4).10
The primary outcomes of the volunteer infection 
study and secondary outcomes of the single ascending 
dose study were the following pharmacokinetic 
parameters: maximum observed concentration (Cmax); 
time to reach Cmax (tmax); area under the concentration–
time curve (AUC) from time 0 h (dosing) to the last 
sampling time at which the concentration was greater 
than or equal to the lower limit of quantification (LLOQ; 
AUC0–t); AUC from time 0 h extrapolated to infinity 
(AUC0–∞); AUC from time 0 h to 144 h after dosing 
(AUC0–144h); apparent terminal half-life (t½); apparent total 
clearance (CL/F); apparent volume of distribution 
(Vz/F); time at or above the minimum inhibitory 
concentration (MIC), estimated in mice to be 3 ng/mL 
(t≥3 ng/mL); and time at or above the minimum parasiticidal 
concentration, estimated in mice to be 10 ng/mL 
(t≥10 ng/mL).
Other primary outcomes of the volunteer infection 
study were the parasite reduction ratio (PRR) and the 
corresponding parasite clearance half-life (with the PRR 
expressed as the ratio of the parasite density decrease over 
a 48 h time period following M5717 dosing [PRR48]). Other 
secondary outcomes of the volunteer infection study were 
the malaria clinical score11 (to be presented elsewhere) and 
the incidence of recrudescence. Additional secondary 
outcomes for the single ascending dose study and the 
volunteer infection study were the MIC, minimum 
parasiticidal concentration, parasite clearance time, and 
lag phase (to be calculated using pharmacokinetic–
pharmacodynamic modelling and presented elsewhere). 
Genetic mutations in recrudescent P falciparum 
populations conferring resistance to M5717 were an 
exploratory outcome.
Statistical analysis
The intended sample size in the single ascending dose 
study (eight participants per cohort randomised 3:1 to 
M5717 or placebo) was based on general phase 1 trial 
experience and was considered appropriate to achieve the 
primary objective of this part of the study (determine the 
safety and tolerability of M5717). The intended sample 
size in the volunteer infection study (eight participants 
per cohort) was selected based on several previous 
induced blood-stage malaria studies that successfully 
characterised the parasite clearance kinetics of various 
antimalarial compounds.11–15
Non-compartmental pharmacokinetic analysis was done 
using Phoenix WinNonlin version 8.0. Pharmaco dynamic 
analyses were done in R version 3.5.0. The PRR48 and 
parasite clearance half-life were estimated using the slope 
of the optimal fit for the log-linear relationship of the 
parasitaemia decay, as described previously,16 with 
modification due to the biphasic parasitaemia clearance 
profile observed. The pattern of parasite clearance was 
analysed at the participant level using segmented piecewise 
regression17 to estimate the clearance profile in two phases: 
the first phase corresponding to initial slow clearance, and 
the second to subsequent rapid clearance. Random-effects 
meta-analysis18 was used to calculate cohort-specific 
estimates of clearance (PRR48 and parasite clearance half-
life) and the breakpoint (timepoint when the first clearance 
phase ends and the second clearance phase begins). 
Analyses were done in the per-protocol population.
Role of the funding source
Authors employed by the healthcare business of Merck 
KGaA, Darmstadt, Germany, were involved in protocol 
development, study oversight, and data analysis and 
interpretation. The Wellcome Trust had no role in the 
study apart from representation on the safety monitoring 
committee.
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Results
The study was done from Aug 28, 2017 (first participant 
consented), to June 14, 2019 (last participant’s last visit). 
The dates for each cohort and database lock are presented 
in the appendix (p 16). In total, 221 volunteers were 
screened for eligibility, with 133 excluded (figure 1). 
88 volunteers were enrolled, including 66 in the single 
ascending dose study and 22 in the volunteer infection 
study (figure 1). All participants enrolled in both parts 
were male and the majority self-selected their race 
as White (table 1). The first eight cohorts of the single 
ascending dose study (50–1800 mg) each contained 
eight participants, with six participants randomly assigned 
to M5717 and two randomly assigned to placebo. Several 
transient adverse events were observed following dosing 
of the two sentinel participants (one randomised to M5717 
and one randomised to placebo) in the 2100 mg dose 
cohort, which resulted in the safety monitoring committee 
deciding not to enrol the remaining six participants in this 
cohort. Due to recruitment limitations, the 150 mg 
cohort of the volunteer infection study consisted of 
six participants instead of the planned eight. In total, 
two participants withdrew voluntarily before the end of 
study: one withdrew from the single ascending dose study 
(dosed with 600 mg M5717) on day 11 and one withdrew 
from the volunteer infection study (dosed with 800 mg 
M5717) on day 33. Available data from both participants 
were included in the analyses of study endpoints.
A summary of adverse events reported after dosing 
with M5717 or placebo, including severity and relation-
ship to the investigational product, is presented in 
table 2. Full lists of adverse events by system organ class 
and preferred term and adverse events considered related 
to study treatment are presented in the appendix (pp 2, 6). 
No adverse event in either the single ascending dose study 
or the volunteer infection study was classified as serious, 
and none resulted in study discontinuation. All adverse 
events related to M5717 were mild or moderate in severity, 
transient, and resolved without sequelae. No dose-related 
trends in vital signs, ECGs, or clinical laboratory 
parameters were detected in either the single ascending 
dose study or the volunteer infection study (data not 
shown).
In the single ascending dose study, 37 (76%) of 
49 participants dosed with M5717 and 13 (76%) of 17 dosed 
with placebo experienced at least one adverse event 
(table 2). Adverse events related to M5717 or placebo were 
experienced by 12 (24%) of 49 participants dosed with 
M5717 and three (18%) of 17 dosed with placebo. No 
participant dosed with 50 mg, 100 mg, or 200 mg M5717 
experienced an adverse event related to M5717. One (17%) 
of six participants in each of the 400 mg, 1000 mg, and 
1250 mg M5717 dosing groups, and two (33%) of six in 
the 600 mg M5717 dosing group, experienced at least 
one adverse event related to M5717. All six participants 
dosed with 1800 mg M5717, as well as the single 
individual dosed with 2100 mg, experienced at least 
one adverse event related to M5717. The most commonly 
reported adverse events related to M5717 were headache 
(six participants), blurred vision (four participants), 
dizziness (three participants), and oral hypoesthesia 
(three participants; appendix p 6). Adverse events related 
to M5717 of abdominal discomfort, upper abdominal 
pain, dizziness, hot flush, and mental impairment were 
experienced only by participants dosed with 1800 mg 
M5717, and oral hypoesthesia and blurred vision were 
experienced only by participants dosed with 1800 mg or 
2100 mg M5717 (appendix p 6). The onset of the nervous 
system disorder adverse events of blurred vision, oral 
hypoesthesia, and dizziness was around the time of tmax, 
but we did not consider that there was a relationship with 
peak drug concentration, with these adverse events 
not occurring in some participants with high Cmax 
(appendix p 7).
In the volunteer infection study, 21 (95%) of 22 parti -
cipants experienced at least one adverse event after M5717 
dosing. The majority of adverse events observed in the 
volunteer infection study were mild to moderate signs and 
symptoms that are frequently associated with malaria; the 
incidence of these adverse events declined over the course 
of approximately 7 days after M5717 dosing. Only one 
participant in the volunteer infection study (dosed with 
400 mg M5717) experienced an adverse event related to 
M5717 (mild rhinorrhoea that resolved without sequelae; 
table 2; appendix p 6).
Figure 1: Trial profile
In part one, single ascending doses of M5717 (50–2100 mg) were tested in nine cohorts. The volunteer infection 
study (part two) started after documentation of safety and pharmacokinetics data from the first four cohorts 
(up to the 400 mg dose cohort) in part one. The volunteer infection study consisted of three dose cohorts 
(150, 400, and 800 mg).
133 excluded
 88 eligibility criteria not met
 14 withdrew consent
 31 other reasons
8 each allocated to 50, 100, 200, 400,
    600, 1000, 1250, and 1800 mg cohorts
    randomised 6 M5717 to 2 placebo 
2 allocated to 2100 mg cohort
   Randomised 1 M5717 to 1 placebo
65 completed the study
66 enrolled in part one (single ascending
      dose study)
221 individuals assessed for eligibility
1 discontinued
  (day 11, withdrew consent)
6 allocated to 150 mg cohort
8 allocated to 400 mg cohort
8 allocated to 800 mg cohort
21 completed the study
22 enrolled in part two (volunteer
       infection study)
1 discontinued (day 33, 
    unable to attend final visit)
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M5717 whole-blood concentrations peaked approxi-
mately 2 h after dosing across dose levels in both the 
single ascending dose study and the volunteer infection 
study, and this peak was followed by a biexponential 
decline (figure 2A). Multiple secondary peaks were 
observed around 6–10 h and 30 h after dosing (figure 2B). 
Dose-related increases in exposure were observed across 
the entire dose range evaluated in both the single 
ascending dose study and the volunteer infection study 
(table 3). Median tmax values ranged from 1 h to 7 h across 
dose groups in both the single ascending dose study and 
the volunteer infection study (table 3). Mean t1/2 values 
ranged from 106 h to 193 h and were lower at lower doses 
(≤200 mg), probably because M5717 concentrations fell 
below the LLOQ (1 ng/mL) earlier than in higher-dose 
groups for most participants in the lower-dose groups, 
leading to estimation inaccuracy. At doses above 200 mg, 
mean t1/2 values ranged from 146 h to 193 h. The earlier 
decline below the LLOQ might also have resulted in 
some underestimation of total exposure (AUC0–∞) and 
corresponding overestimation of CL/F at the lower doses. 
Mean Vz/F estimates were high, ranging from 5880 L to 
9510 L across both the single ascending dose study and 
the volunteer infection study. The mean t≥3 ng/mL and t≥10 ng/mL 
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Data are mean (SD) or n (%). 100% of participants in all groups were male. NC=not calculable.
Table 1: Demographic profile of participants by dose cohort



























Any adverse event 13 (76%) 6 (100%) 5 (83%) 3 (50%) 4 (67%) 3 (50%) 4 (67%) 5 (83%) 6 (100%) 1 (100%) 6 (100%) 8 (100%) 7 (88%)
Related to study 
treatment
3 (18%) 0 0 0 1 (17%) 2 (33%) 1 (17%) 1 (17%) 6 (100%) 1 (100%) 0 1 (13%) 0
Moderate adverse event 
(grade 2)
1 (6%) 1 (17%) 1 (17%) 0 0 1 (17%) 0 1 (17%) 0 1 (100%) 2 (33%) 3 (38%) 2 (25%)
Related to study 
treatment
0 0 0 0 0 0 0 1 (17%) 0 1 (100%) 0 0 0
Severe adverse event 
(grade 3)
0 1 (17%) 0 0 0 0 0 0 0 0 0 0 1 (13%)
Data are number of participants with at least one adverse event observed after dosing with M5717 or placebo (%). There were no serious adverse events, adverse events resulting in study discontinuation, grade 3 
adverse events related to study treatment, or grade 4 adverse events reported in this study. The medical assessment of adverse event severity was done in accordance with the Qualitative Toxicity Scale10 
(mild=grade 1, moderate=grade 2, severe=grade 3, potentially life threatening=grade 4).
Table 2: Adverse event summary by dose cohort
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Figure 2: M5717 whole blood concentration–time profiles by dose cohort in the SAD and VIS (A and C) and individual-participant parasitaemia–time profiles in the VIS (B, D, and E)
Plots represent mean values with SD (error bars) of the M5717 concentration of each dose cohort over the entire study (A) or over the first 48 h after dosing (C). Horizontal dotted lines indicate the 
minimum inhibitory concentration (3 ng/mL) and minimum parasiticidal concentration (10 ng/mL) estimated from preclinical efficacy studies in mice.4 For the purpose of graphing on a log10 
logarithmic scale, timepoints at which M5717 could not be detected were substituted with a value of 1 ng/mL (the lower limit of quantitation). In the VIS, participants were inoculated intravenously 
with Plasmodium falciparum-infected erythrocytes and administered a single oral dose of 150 mg (B), 400 mg (D), or 800 mg (E) M5717 after 8 days (indicated by the vertical dashed line). 
Artemether–lumefantrine (six oral doses taken over 60 h; total dose of 480 mg artemether and 2∙88 g lumefantrine) was administered in response to recrudescence of parasitaemia or 
21 days after M5717 dosing if recrudescence was not observed. For the purpose of graphing on a log10 logarithmic scale, timepoints at which parasitaemia could not be detected were 
substituted with a value of 1 parasite per mL. SAD=single ascending dose study. VIS=volunteer infection study.
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increased with dose over the entire dose range in both 
the single ascending dose study and the volunteer 
infection study. Coefficients of variation ranged 
from 23∙9% to 44∙3% for AUC0–∞, and from 19∙7% 
to 54∙3% for Cmax, which is comparable to the variability 
observed for other substrates of CYP3A4.19 At doses of 
150 mg and higher, M5717 concentrations were at least 
3 ng/mL for at least 168 h in all participants, and at doses 
of 400 mg or higher, M5717 concentrations were 
10 ng/mL or higher for at least 168 h in all participants. 
No discernible differences or trends were observed 
in pharmacokinetic parameters between the single 
ascending dose study and the volunteer infection study. 
The statistical assessment of dose proportionality of 
exposure across both the single ascending dose study and 
the volunteer infection study suggested a slightly greater-
than-proportional increase for all AUC parameters and 
Cmax (slope estimates of 1∙16–1∙32 for AUC parameters 
and 1∙48 for Cmax; 90% CI above 1∙00 for all parameters; 
data not shown in full). The apparent deviation from 
proportionality was small, and in the case of the AUC 
parameters, might be at least partially attributable to the 
underestimation at the lower doses.
The progression of parasitaemia after challenge in 
the volunteer infection study was somewhat variable 
between participants, particularly in the 800 mg cohort 
(figure 2C–E). The geometric mean parasitaemia at 
time of M5717 dosing was 18 931 parasites per mL 
(range 3362–58 958), 9912 parasites per mL (395–45 969), 
and 1857 parasites per mL (13–18 170) for the 150 mg, 
400 mg, and 800 mg cohorts, respectively. Parasite 
clearance occurred in all participants following M5717 
dosing, exhibiting a biphasic profile with parasitaemia 
decreasing slowly for 35–55 h after dosing, followed by 
rapid clearance. The breakpoint between the two phases 
and clearance kinetics for each phase were calculated 
(table 4; appendix p 8). The analysis of the 400 mg cohort 
(the first cohort enrolled in the volunteer infection study) 
was confounded by limited qPCR sampling under taken 
across the timepoints when the second phase of 
clearance began, probably influencing the accuracy of the 
estimates. Two participants in this cohort were excluded 
from the cohort-specific estimates because the breakpoint 
between clearance phases for these individuals occurred 
later than in other participants in the cohort, resulting in 
insufficient datapoints to appropriately characterise the 
clearance slope of the second phase. Sampling timepoints 
for qPCR in the 150 mg and 800 mg cohorts were 
amended to enable estimation of clearance parameters 
with greater confidence. One participant in the 800 mg 
cohort was excluded from the cohort-specific estimates 
because parasitaemia was very low (13 parasites per mL 

























































































































































































































































Data are geometric means (coefficient of variation [%]) except tmax, which is median (range). AUC0–∞=area under the concentration–time curve from time 0 h (dosing) 
extrapolated to infinity. AUC0–t=area under the concentration–time curve from time 0 h (dosing) to the last sampling time at which the concentration was at or above the 
lower limit of quantification. AUC0–144h=area under the concentration–time curve from time 0 h (dosing) to 144 h after dosing. Cmax=maximum observed concentration. 
tmax=time to reach the maximum observed concentration. t½=apparent terminal half-life. CL/F=apparent total clearance. Vz/F=apparent volume of distribution. t≥3 ng/mL=time 
at or above the predicted minimum inhibitory concentration, calculated in mice to be 3 ng/mL. t≥10 ng/mL=time at or above the predicted minimum parasiticidal 
concentration, calculated in mice to be 10 ng/mL. ND=not determined. *Descriptive statistics were not calculated since N=1. †Pharmacokinetic diagnostics indicated 
non-reliability of the elimination rate constant estimate in ≥50% of participants, affecting related pharmacokinetic parameters. ‡Concentrations were below 
10 ng/mL at all timepoints in almost all participants.
Table 3: Pharmacokinetic parameters by dose cohort
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at the time of dosing), resulting in difficulties in 
fitting the segmented regression. The reason for the 
low parasitaemia in this participant was unclear; the 
investigator confirmed that the participant did not 
meet the exclusion criteria associated with previous or 
concomitant medications and travel to malaria-endemic 
regions, and no errors in preparation of the malaria 
parasite inoculum were identified. The breakpoint 
between the two parasite clearance phases occurred later 
in the higher-dose cohorts than in the lowest-dose cohort. 
For all cohorts, parasite clearance was considerably faster 
during the second phase than in the first phase. There 
were differences in clearance kinetics between the 
150 mg and 800 mg cohorts for both phases (95% CIs for 
PRR48 and half-life do not overlap; table 4). However, 
definitive comparisons between the 400 mg cohort and 
the other cohorts were limited by the aforementioned 
sampling timepoint issues.
Recrudescence occurred in three (50%) of six participants 
in the 150 mg cohort (10, 11, and 19 days after M5717 
dosing) and in two (25%) of eight in the 400 mg cohort 
(both at 12 days after M5717 dosing). No recrudescence 
was observed in the 800 mg cohort up to 21 days after 
dosing. All participants were treated with artemether–
lumefantrine per protocol and were confirmed to be 
aparasitaemic by the end of the study. Sequencing of the 
full-length P falciparum eEF2 gene was undertaken 
with recrudescent parasites from all five participants 
who experienced recrudescence (appendix p 10). Single-
nucleotide polymorphisms were detected in four of the 
five recrudescent parasite populations (in two of three 
participants in the 150 mg cohort and both participants in 
the 400 mg cohort), resulting in amino acid substitutions 
at positions 134 (Glu to Gln), 183 (Ile to Met), 474 (Ser to 
Arg), and 754 (Pro to Ala) in PfeEF2.
Discussion
This study represents the first clinical investigation of 
the safety, pharmacokinetics, and antimalarial activity of 
M5717, the first plasmodium eEF2 inhibitor to reach 
clinical development. A major strength of this study is 
the combining of the single ascending dose study with 
the volunteer infection study in a first in-human study to 
accelerate early clinical evaluation of this compound. 
This approach enabled the rapid accrual of key safety and 
efficacy data.
Safety results indicated that M5717 is well tolerated 
when administered to healthy individuals as a single oral 
dose. No serious adverse events were observed during 
the study, and all adverse events considered related to 
M5717 were mild or moderate in severity and transient in 
nature. The incidence of M5717-related adverse events 
was low at doses up to and including 1250 mg 
(one [17%] of six participants dosed with 1250 mg M5717 
in the single ascending dose study experienced at least 
one treatment-related adverse event). The side-effects of 
transient oral hypoesthesia and blurred vision (both 
mild or moderate in severity), which occurred among 
participants administered 1800 mg or 2100 mg M5717, 
were considered to be possible concentration-related 
parasympathetic effects. As nervous system disorder-
related adverse events were not predicted from the 
animal toxicity studies, these adverse events were 
considered to constitute an unknown risk and, since 
multiples of the predicted therapeutic dose and exposure 
were reached, further dosing was suspended after dosing 
of the two sentinel participants in the 2100 mg cohort.
The pharmacokinetic profile of M5717 observed in 
humans confirms the potential for the compound to be 
developed as a new antimalarial. M5717 was rapidly 
absorbed following oral administration (maximum blood 
concentrations occurred between 1 h and 7 h after 
administration), and a very long half-life was observed 
(146–193 h at doses >200 mg), which is substantially longer 
than the half-life observed in preclinical animal studies 
following oral administration of 3–5 mg/kg (18–20 h).4 For 
all participants administered a dose of 400 mg or higher, 
M5717 blood concentrations remained above the minimum 
parasiticidal concentration estimated in the preclinical 
mouse efficacy model (10 ng/mL)4 for at least 7 days, which 
is longer than three parasite replication cycles. Preclinical 
studies indicated that M5717 is a substrate of cytochrome 
P450 3A4 (CYP3A4), with no active or toxic metabolites 
identified. Future drug–drug interaction studies will be 
needed to explore the effect of CYP3A4 inducers and 
inhibitors on M5717 pharmacokinetics.
N PRR48 (95% CI) Parasite clearance half-life, h (95% CI) Breakpoint between 
first and second phases, 
h (95% CI)
First phase Second phase First phase Second phase
150 mg 6 1∙15 (0∙59 to 2∙25) 12 892 (3858 to 43 081) 231∙1 (40∙9 to not reached) 3∙5 (3∙1 to 4∙0) 35∙8 (31∙3 to 40∙3)
400 mg 6* 1∙73 (1∙27 to 2∙37) 5127 (1006 to 26 132) 60∙4 (38∙6 to 138∙6) 3∙9 (3∙3 to 4∙8) 54∙4 (47∙2 to 61∙6)
800 mg 7† 3∙86 (2∙90 to 5∙13) 436 (179 to 1061) 24∙7 (20∙4 to 31∙3) 5∙5 (4∙8 to 6∙4) 55∙7 (52∙9 to 58∙5)
Data represent cohort-specific estimates for each parameter calculated using random-effects meta-analysis.18 PRR48=parasite reduction ratio after treatment standardised 
over a 48 h period. *Two participants were excluded from analyses in the 400 mg cohort since the breakpoint for these individuals occurred later than in other participants in 
the cohort and there were insufficient datapoints to appropriately characterise the second phase slope. †One participant was excluded from analyses in the 800 mg cohort 
because parasitaemia was very low throughout the study, resulting in difficulties in fitting the segmented regression.
Table 4: Parasite clearance parameters in the volunteer infection study
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Results obtained in the volunteer infection study indicate 
that M5717 has potent blood-stage antimalarial activity in 
humans. Single oral doses of 150, 400, or 800 mg M5717 
were able to clear P falciparum parasitaemia initially. 
Doses of 150 mg or 400 mg were insufficient to prevent 
recrudescence in all participants, whereas no participant 
developed recurrent parasitaemia up to 21 days after 
dosing when administered 800 mg. The curative 
dose of M5717 will be estimated with population 
pharmacokinetic–pharmacodynamic modelling using 
data from this study, as previous studies have 
demonstrated a correlation between curative dose 
predictions from volunteer infection study data and 
clinical trial results.13,20,21 Importantly, the tolerability of 
single doses of M5717 above 800 mg was demonstrated 
in the single ascending dose study. Thus, a safety margin 
has been established in case of need for higher exposure 
in patients with higher parasitaemia burden and any 
differences in pharmacokinetics or pharmacodynamics 
in the target population for treatment.
The biphasic clearance profile observed following 
M5717 administration, with an initial period of slow 
clearance lasting 35–55 h (clearance half-life 24∙7 h in the 
800 mg cohort), followed by a rapid clearance phase 
(clearance half-life 5∙5 h in the 800 mg cohort), was 
consistent with the antimalarial activity observed in vitro 
and in the mouse efficacy model, wherein a lag of 24–48 h 
was evident.4 Given that maximum blood concentrations 
of M5717 were reached 1–7 h after dosing, the apparent 
lag in parasite killing might reflect the mode of action 
of the compound in inhibiting protein synthesis. 
Alternatively, the lag might be due to the fact that the 
qPCR assay used to quantify parasitaemia measured all 
parasites in circulation (viable, damaged, or dead) and 
did not directly measure the rate of parasite killing. If the 
lag in parasite killing is indeed a true phenomenon, it 
suggests M5717 might need a partner drug that has a fast 
action with relatively long exposure if an indication for 
combined treatment of clinical disease is planned.
The importance of partnering M5717 with another 
antimalarial with a distinct mode and rapid onset of 
action is further highlighted by the finding that four of 
five parasite recrudescences had acquired genetic 
mutations in the target gene PfeEF2 that are associated 
with resistance. All four unique amino acid substitutions 
occurred at or near mutations that have been previously 
identified in drug-resistant parasites obtained in vitro.4 In 
resistance-selection studies with P falciparum asexual 
blood-stage parasites, these mutations generally afforded 
five-fold to 40-fold increases in half-maximal growth 
inhibition concentration, with a minimum inoculum 
of resistance of approximately 107 parasites, similar 
to the rate of resistance observed with the P-type 
ATPase 4 (PfATP4) inhibitor cipargamin22 and the 
dihydroorotate dehydr ogenase (DHODH) inhibitor 
DSM265.23 In earlier studies, point mutations in PfeEF2 
resulted in a fitness cost to parasites, manifesting as 
reduced rates of parasite growth.4 Of note, in an in-vitro 
and in-vivo study using the mouse efficacy model 
wherein the hemozoin-formation inhibitor pyronaridine 
(a com ponent of an approved artemisinin combination 
therapy) was partnered with M5717, pyronaridine 
prevented selection of M5717-resistant mutants, and 
M5717 did not negatively impact the rate of killing of the 
faster-acting pyronaridine.24 Furthermore, M5717 was 
previously shown to be highly effective against multiple 
P falciparum and Plasmodium vivax field isolates, as well 
as P falciparum culture-adapted lines resistant to 
chloroquine, pyrime thamine, and mefloquine.4
Although this study provides valuable first-in-human 
data on M5717, it has limitations. First, although women 
of non-childbearing potential were eligible for inclusion, 
none were enrolled. Therefore, it will be important to test 
for sex differences in safety and pharmacokinetics in 
future studies. Similarly, it will be important to 
investigate ethnic differences in these parameters, 
particularly in the target population in countries endemic 
for malaria. This study also did not investigate the effect 
of food on the pharmacokinetic profile of M5717. The 
variability in parasitaemia between cohorts at the time of 
dosing might have influenced the incidence of 
recrudescence observed, and the fact that definitive 
antimalarial treatment was initiated 21 days after dosing 
might have prevented observation of some late recru-
descences. However, as noted already, pharma cokinetic–
pharmacodynamic modelling is the preferred method for 
dose selection in early phase antimalarial drug 
development. The parasite clearance rate estimates are 
not expected to have been affected by variability in 
parasitaemia at the time of dosing because parasite 
clearance after treatment is considered a first-order 
process.25 Although volunteer infection studies have 
been shown to predict the activity of investigational 
antimalarials in studies in endemic populations,12,13,20,26 
further study of the pharma codynamic effect of M5717 in 
such populations will be required to confirm that the 
selected dose is sufficient to effect cure.
In conclusion, this first-in-human study of the novel 
plasmodium eEF2 inhibitor M5717 supports its further 
clinical development as a new antimalarial. M5717 was 
well tolerated in healthy participants at doses that clear 
blood-stage P falciparum, and the long half-life of the 
compound indicates the potential for single-dose 
administration. The selection for resistance arising in 
these single-dose trials, which was also observed in a 
field trial on single dosing with the mitochon drial 
DHODH inhibitor DSM265,20 suggests that additional 
doses might be needed to mitigate the risk of resistance 
selection. Future studies to investigate combination 
therapies of M5717 with a fast-acting partner drug in 
treating clinical malaria are warranted, as are 
investigations into the use of M5717 for other indications, 
including chemoprotection, prophylaxis, and trans-
mission blocking.
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